Last reviewed · How we verify
MEDI-493
At a glance
| Generic name | MEDI-493 |
|---|---|
| Also known as | Synagis |
| Sponsor | MedImmune LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fever
- Rash
- Anaphylaxis
- Severe thrombocytopenia
- Injection site reactions
Key clinical trials
- Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease (NA)
- Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) (PHASE3)
- Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. (PHASE2)
- A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers. (PHASE1)
- A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children (PHASE2, PHASE3)
- Adherence to Palivizumab Prophylaxis (NA)
- Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Vaccine Against Respiratory Syncytial Virus (PHASE1)
- Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI-493 CI brief — competitive landscape report
- MEDI-493 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI